Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication

Journal of Medicinal Chemistry

Volumn 56, Issue 6, 2013, Pages 2270-2282

  Barreca, Maria Letizia ^a   Manfroni, Giuseppe ^a   Leyssen, Pieter ^b   Winquist, Johan ^c   Kaushik Basu, Neerja ^d   Paeshuyse, Jan ^b   Krishnan, Ramalingam ^d   Iraci, Nunzio ^a   Sabatini, Stefano ^a   Tabarrini, Oriana ^a   Basu, Amartya ^d   Danielson, U Helena ^c   Neyts, Johan ^b   Cecchetti, Violetta ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UPPSALA UNIVERSITY   (Sweden)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 FLUOROPHENYL) 4 METHYL N [4 ((METHYLSULFONYL)AMINO) PHENYL] 1,4 DIHYDROPYRAZOLO[4,3 C]]BENZOTHIAZINE 3 CARBOXAMIDE 5,5 DIOXIDE; ANTIVIRUS AGENT; NONSTRUCTURAL PROTEIN 5B; RNA POLYMERASE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG IDENTIFICATION; HEPATITIS C VIRUS; NONHUMAN; STRUCTURE ANALYSIS; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DRUG DESIGN; HEPACIVIRUS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PYRAZOLES; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84875701234     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301643a     Document Type: Article

References (47)

1. Sy, T.; Jamal, M. M. Epidemiology of Hepatitis C Virus (HCV) Infection Int. J. Med Sci. 2006, 3, 41-46
2. Factsheet No. 164, July 2011; World Health Organization: Geneva, 2011; http://www.who.int/mediacentre/factsheets/fs164/en/ (accessed September 30, 2012).
3. Seeff, L. B. Natural History of Chronic Hepatitis C Hepatology 2002, 36, S35-S46
4. Scheridan, C. New Merck and Vertex Drugs Raise Standard of Care in Hepatitis C Nature Biotechnol. 2011, 29, 553-554
5. Ferenci, P.; Reddy, K. R. Impact of HCV Protease-Inhibitor-Based Triple Therapy for Chronic HCV Genotype 1 Infection Antiviral Ther. 2011, 16, 1187-1201
6. Pawlotsky, J. M.; Chevaliez, S.; McHutchison, J. G. The Hepatitis C Virus Life Cycle as a Target for New Antiviral Therapies Gastroenterology 2007, 132, 1979-1998
7. Behrens, S. E.; Tomei, L.; De Francesco, R. Identification and Properties of the RNA-Dependent RNA Polymerase of Hepatitis C Virus EMBO J. 1996, 15, 12-22
8. Wu, J. Z.; Hong, Z. Targeting NS5B RNA-Dependent RNA Polymerase for Anti-HCV Chemotherapy Curr. Drug Targets Infect. Disord. 2003, 3, 207-219
9. Sofia, M. J.; Chang, W.; Furman, P. A.; Mosley, R. T.; Ross, B. S. Nucleoside, Nucleotide, and Non-Nucleoside Inhibitors of Hepatitis C Virus NS5B RNA-Dependent RNA-Polymerase J. Med. Chem. 2012, 55, 2481-2531
10. Mayhoub, A. S. Hepatitis C RNA-Dependent RNA Polymerase Inhibitors: a Review of Structure-Activity and Resistance Relationships; Different Scaffolds and Mutations Bioorg. Med. Chem. 2012, 20, 3150-3161
11. Barreca, M. L.; Iraci, N.; Manfroni, G.; Cecchetti, V. Allosteric Inhibition of the Hepatitis C Virus NS5B Polymerase: in Silico Strategies for Drug Discovery and Development Future Med. Chem. 2011, 3, 1027-1055
12. Manfroni, G.; Paeshuyse, J.; Massari, S.; Zanoli, S.; Gatto, B.; Maga, G.; Tabarrini, O.; Cecchetti, V.; Fravolini, A.; Neyts, J. Inhibition of Subgenomic Hepatitis C Virus RNA Replication by Acridone Derivatives: Identification of an NS3 Helicase Inhibitor J. Med. Chem. 2009, 52, 3354-3365
13. Manfroni, G.; Meschini, F.; Barreca, M. L.; Leyssen, P.; Samuele, A.; Iraci, N.; Sabatini, S.; Massari, S.; Maga, G.; Neyts, J.; Cecchetti, V. Pyridobenzothiazole Derivatives as New Chemotype Targeting the HCV NS5B Polymerase Bioorg. Med. Chem. 2012, 20, 866-876
14. Nichols, D. B.; Fournet, G.; Gurukumar, K. R.; Basu, A.; Lee, J. C.; Sakamoto, N.; Kozielskie, F.; Musmuca, I.; Joseph, B.; Ragno, R.; Kaushik-Basu, N. Inhibition of Hepatitis C Virus NS5B Polymerase by S -Trityl- l -Cysteine Derivatives Eur. J. Med. Chem. 2012, 49, 191-199
15. Musmuca, I.; Caroli, A.; Mai, A.; Kaushik-Basu, N.; Arora, P.; Ragno, R. Combining 3-D Quantitative Structure-Activity Relationship with Ligand Based and Structure-Based Alignment Procedures for in Silico Screening of New Hepatitis C virus NS5B Polymerase Inhibitors J. Chem. Inf. Model. 2010, 50, 662-676
16. Das, D.; Hong, J.; Chen, S. H.; Wang, G.; Beigelman, L.; Seiwert, S. D.; Buckman, B. O. Recent Advances in Drug Discovery of Benzothiadiazine and Related Analogs as HCV NS5B Polymerase Inhibitors Bioorg. Med. Chem. 2011, 19, 4690-4703
17. de Vicente, J.; Hendricks, R. T.; Smith, D. B.; Fell, J. B.; Fischer, J.; Spencer, S. R.; Stengel, P. J.; Mohr, P.; Robinson, J. E.; Blake, J. F.; Hilgenkamp, R. K.; Yee, C.; Adjabeng, G.; Elworthy, T. R.; Tracy, J.; Chin, E.; Li, J.; Wang, B.; Bamberg, J. T.; Stephenson, R.; Oshiro, C.; Harris, S. F.; Ghate, M.; Leveque, V.; Najera, I.; Le Pogam, S.; Rajyaguru, S.; Ao-Ieong, G.; Alexandrova, L.; Larrabee, S.; Brandl, M.; Briggs, A.; Sukhtankar, S.; Farrell, R.; Xu, B. Non-Nucleoside Inhibitors of HCV Polymerase NS5B. Part 2: Synthesis and Structure-Activity Relationships of Benzothiazine-Substituted Quinolinediones Bioorg. Med. Chem. Lett. 2009, 19, 3642-3646
18. LigPrep, version 2.5; Schrödinger, LLC: New York, 2011.
19. Glide, version 5.6; Schrödinger, LLC, New York, 2010.
20. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, M. P.; Knoll, E. H.; Shaw, D. E.; Shelley, M.; Perry, J. K.; Francis, P.; Shenkin, P. S. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy J. Med. Chem. 2004, 47, 1739-1749
21. Halgren, T. A.; Murphy, R. B.; Friesner, R. A.; Beard, H. S.; Frye, L. L.; Pollard, W. T.; Banks, J. L. Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening J. Med. Chem. 2004, 47, 1750-1759
22. Friesner, R. A.; Murphy, R. B.; Repasky, M. P.; Frye, L. L.; Greenwood, J. R.; Halgren, T. A.; Sanschagrin, P. C.; Mainz, D. T. Extra Precision Glide: Docking and Scoring Incorporating a Model of Hydrophobic Enclosure for Protein-Ligand Complexes J. Med. Chem. 2006, 49, 6177-6196
23. Cecchetti, V.; Fravolini, A.; Schiaffella, F.; De Regis, M.; Orzalesi, G.; Volpato, I. Synthesis and Pharmacological Activity of Pyrazolo-1,2- benzothiazine- and Isoxazolo-1,2-benzothiazinecarboxamides Farmaco 1983, 38, 35-44
24. Hang, J. Q.; Yang, Y.; Harris, S. F.; Leveque, V.; Whittington, H. J.; Rajyaguru, S.; Ao-Ieong, G.; McCown, M. F.; Wong, A.; Giannetti, A. M.; Le Pogam, S.; Talamás, F.; Cammack, N.; Nájera, I.; Klumpp, K. Slow binding inhibition and mechanism of resistance of non-nucleoside polymerase inhibitors of hepatitis C virus J. Biol. Chem. 2009, 284, 15517-15529
25. Cheng, C. C.; Shipps, G. W., Jr.; Yang, Z.; Kawahata, N.; Lesburg, C. A.; Duca, J. S.; Bandouveres, J.; Bracken, J. D.; Jiang, C. K.; Agrawal, S.; Ferrari, E.; Huang, H. C. Inhibitors of Hepatitis C Virus Polymerase: Synthesis and Characterization of Novel 2-oxy-6-Fluoro- N -((S)-1-hydroxy-3-phenylpropan- 2-yl)-benzamides Bioorg. Med. Chem. Lett. 2010, 20, 2119-2124
26. Di Marco, S.; Volpari, C.; Tomei, L.; Altamura, S.; Harper, S.; Narjes, F.; Koch, U.; Rowley, M.; De Francesco, R.; Migliaccio, G.; Carfi, A. Interdomain Communication in Hepatitis C Virus Polymerase Abolished by Small Molecule Inhibitors Bound to a Novel Allosteric Site J. Biol. Chem. 2005, 280, 29765-29770
27. Li, H.; Tatlock, J.; Linton, A.; Gonzalez, J.; Jewell, T.; Patel, L.; Ludlum, S.; Drowns, M.; Rahavendran, S. V.; Skor, H.; Hunter, R.; Shi, S. T.; Herlihy, K. J.; Parge, H.; Hickey, M.; Yu, X.; Chau, F.; Nonomiya, J.; Lewis, C. Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7- dimethyl-[1,2,4]triazolo[1,5- a ]pyrimidin-2-yl)methyl)-4-hydroxy-5,6- dihydropyran-2-one (PF-00868554) as a Potent and Orally Available Hepatitis C Virus Polymerase Inhibitor J. Med. Chem. 2009, 52, 1255-1258
28. Sabatini, S.; Gosetto, F.; Serritella, S.; Manfroni, G.; Tabarrini, O.; Iraci, N.; Brincat, J. P.; Carosati, E.; Villarini, M.; Kaatz, G. W.; Cecchetti, V. Pyrazolo[4,3- c ][1,2]benzothiazines 5,5-Dioxide: A Promising New Class of Staphylococcus Aureus NorA Efflux Pump Inhibitors J. Med. Chem. 2012, 55, 3568-3572
29. Waslei, J.; Rosenthal, G. J.; Sun, X.; Strong, S.; Qiu, J. Novel Pyrrole Inhibitors of S -Nitrosoglutathione Reductase as Therapeutic Agents. PTC WO 2010/019903 A1, 2010.
30. Wang, Y.; Guziec, F. S. A Convenient Reductive Deamination (Hydrodeamination) of Aromatic Amines J. Org. Chem. 2001, 66, 8293-8296
31. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand Efficiency: a Useful Metric for Lead Selection Drug Discovery Today 2004, 9, 430-431
32. Reynolds, C. H.; Tounge, B. A.; Bembenek, S. D. Ligand Binding Efficiency: Trends, Physical Basis, and Implications J. Med. Chem. 2008, 51, 2432-2438
33. Leeson, P. D.; Springthorpe, B. The Influence of Drug-Like Concepts on Decision-Making in Medicinal Chemistry Nature Rev. Drug Discovery 2007, 6, 881-890
34. QikPro, version 3.5; Schrödinger, LLC: New York, 2012.
35. Kaushik-Basu, N.; Bopda-Waffo, A.; Talele, T. T.; Basu, A.; Costa, P. R.; da Silva, A. J.; Sarafianos, S. G.; Noel, F. Identification and Characterization of Coumestans as Novel HCV NS5B Polymerase Inhibitors Nucleic Acids Res. 2008, 36, 1482-1496
36. Chen, Y.; Bopda-Waffo, A.; Basu, A.; Krishnan, R.; Silberstein, E.; Taylor, D. R.; Talele, T. T.; Arora, P.; Kaushik-Basu, N. Characterization of Aurintricarboxylic Acid as a Potent Hepatitis C Virus Replicase Inhibitor Antivir. Chem. Chemother. 2009, 20, 19-36
37. Tedesco, R.; Shaw, A. N.; Bambal, R.; Chai, D.; Concha, N. O.; Darcy, M. G.; Dhanak, D.; Fitch, D. M.; Gates, A.; Gerhardt, W. G.; Halegoua, D. L.; Han, C.; Hofmann, G. A.; Johnston, V. K.; Kaura, A. C.; Liu, N.; Keenan, R. M.; Lin-Goerke, J.; Sarisky, R. T.; Wiggall, K. J.; Zimmerman, M. N.; Duffy, K. J. 3-(1,1-Dioxo-2 H -(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1 H)-quinolinones, Potent Inhibitors of Hepatitis C Virus RNA-dependent RNA Polymerase J. Med. Chem. 2006, 49, 971-983
38. Tarcsay, A.; Nyíri, K.; Keseru, G. M. Impact of Lipophilic Efficiency on Compound Quality J. Med. Chem. 2012, 55, 1252-1260
39. Christiansen, E.; Due-Hansen, M. E.; Urban, C.; Grundmann, M.; Schröder, R.; Hudson, B. D.; Milligan, G.; Cawthorne, M. A.; Kostenis, E.; Kassack, M. U.; Ulven, T. Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonists: Mesylpropoxy Appendage Lowers Lipophilicity and Iimproves ADME Properties J. Med. Chem. 2012, 55, 6624-6628
40. Cid, J. M.; Tresadern, G.; Vega, J. A.; de Lucas, A. I.; Matesanz, E.; Iturrino, L.; Linares, M. L.; Garcia, A.; Andrés, J. I.; Macdonald, G. J.; Oehlrich, D.; Lavreysen, H.; Megens, A.; Ahnaou, A.; Drinkenburg, W.; Mackie, C.; Pype, S.; Gallacher, D.; Trabanco, A. A. Discovery of 3-Cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4] triazolo[4,3- a ]pyridine (JNJ-42153605): A Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor J. Med. Chem. 2012, 55, 8770-8789
41. Epik, version 2.2; Schrödinger, LLC: New York, 2011
42. Impact, version 5.7; Schrödinger, LLC: New York, 2011
43. Prime, version 2.3; Schrödinger, LLC, New York, NY, 2011.
44. Maestro, version 9.2; Schrödinger, LLC: New York, 2011.
45. The PyMOL Molecular Graphics System, version 1.5.0.4; Schrödinger, LLC: New York, 2013.
46. Winquist, J.; Abdurakhmanov, E.; Baraznenok, V.; Henderson, I.; Vrang, L.; Danielson, U. H. Resolution of the Interaction Mechanisms and Characteristics of Non-nucleoside Inhibitors of Hepatitis C Virus Polymerase Antiviral Res. 2012, 97, 356-368
47. Vrolijk, J. M.; Kaul, A.; Hansen, B. E.; Lohmann, V.; Haagmans, B. L.; Schalm, S. W.; Bartenschlager, R. A Replicon-Based Bioassay for the Measurement of Interferons in Patients with Chronic Hepatitis C J. Virol. Methods 2003, 110, 201-209